Abstract
Opiate substitution therapies have largely contributed to improving outcomes in opiate dependent patients. Their impact has significantly diminished HIV transmission rates, decreased incidence of overdose and reduced delinquency due to heroin trafficking. Since then, some advances have been made in the formulations and dosing regimen of these treatments. They have also largely facilitated opiate withdrawal. However, concerning the maintenance of opiate abstinence, very few new treatments have been proposed. Despite considerable advances in our knowledge of the neurobiological mechanisms of opiate dependence, few clinical trials have been proposed to test new molecules both in accompanying opiate substitution and in maintaining abstinence from illicit opiate use. The objective of this article is to examine the evidence concerning the treatment of opiate dependent patients, especially new treatments and to examine the eventual gaps between currently knowledge, available treatment and demands.
Keywords: Opiate substitution treatment, opiate withdrawal, methadone, buprenorphine, naltrexone, lofexidine, clonidine, Opiate, delinquency, illicit, psychotherapy, fibrillation, enantiomers, arrhythmias, morphine, psychiatric, psychoactive, benzodiazepines
Current Pharmaceutical Design
Title: Pharmacological Treatments of Opiate Dependence
Volume: 17 Issue: 14
Author(s): Amine Benyamina, Michel Reynaud, Lisa Blecha and Laurent Karila
Affiliation:
Keywords: Opiate substitution treatment, opiate withdrawal, methadone, buprenorphine, naltrexone, lofexidine, clonidine, Opiate, delinquency, illicit, psychotherapy, fibrillation, enantiomers, arrhythmias, morphine, psychiatric, psychoactive, benzodiazepines
Abstract: Opiate substitution therapies have largely contributed to improving outcomes in opiate dependent patients. Their impact has significantly diminished HIV transmission rates, decreased incidence of overdose and reduced delinquency due to heroin trafficking. Since then, some advances have been made in the formulations and dosing regimen of these treatments. They have also largely facilitated opiate withdrawal. However, concerning the maintenance of opiate abstinence, very few new treatments have been proposed. Despite considerable advances in our knowledge of the neurobiological mechanisms of opiate dependence, few clinical trials have been proposed to test new molecules both in accompanying opiate substitution and in maintaining abstinence from illicit opiate use. The objective of this article is to examine the evidence concerning the treatment of opiate dependent patients, especially new treatments and to examine the eventual gaps between currently knowledge, available treatment and demands.
Export Options
About this article
Cite this article as:
Benyamina Amine, Reynaud Michel, Blecha Lisa and Karila Laurent, Pharmacological Treatments of Opiate Dependence, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150855
DOI https://dx.doi.org/10.2174/138161211796150855 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Scopolamine and Depression: A Role for Muscarinic Antagonism?
CNS & Neurological Disorders - Drug Targets Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design A Novel Therapeutic Strategy Against Vascular Disorders with Chymase Inhibitor
Current Vascular Pharmacology Activated Carbon/MoO<sub>3</sub>: Efficient Catalyst for Green Synthesis of Chromeno[<i>d</i>]pyrimidinediones and Xanthenones
Combinatorial Chemistry & High Throughput Screening Pathogenesis of Diabetic Retinopathy and Diabetic Macular Edema and Enzyme Inhibition
Current Enzyme Inhibition Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Hairy Roots, their Multiple Applications and Recent Patents
Recent Patents on Biotechnology Role of Heme Oxygenase-1 in Vascular Disease
Current Pharmaceutical Design Lipotoxicity on the Basis of Metabolic Syndrome and Lipodystrophy in HIV-1-Infected Patients Under Antiretroviral Treatment
Current Pharmaceutical Design Renin--Angiotensin System Gene Polymorphism and Regression of Left Ventricular Hypertrophy in Hypertension
Current Pharmacogenomics Unraveling Monoamine Receptors Involved in the Action of Typical and Atypical Antipsychotics on Glutamatergic and Serotonergic Transmission in Prefrontal Cortex
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) A Walk in Nature: Sesquiterpene Lactones as Multi-Target Agents Involved in Inflammatory Pathways
Current Medicinal Chemistry Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Magnesium as a Neuroprotective Agent in Cerebral Ischemia
Current Medicinal Chemistry - Central Nervous System Agents Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Current Pharmaceutical Design Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies
Current Drug Targets Comparison of the Mean Minimum Dose of Bolus Oxytocin for Proper Uterine Contraction during Cesarean Section
Current Clinical Pharmacology Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued)